const {
  Document, Packer, Paragraph, TextRun, HeadingLevel, AlignmentType,
  UnderlineType, SectionType
} = require('docx');
const fs = require('fs');

function heading1(text) {
  return new Paragraph({
    text: text,
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 320, after: 160 }
  });
}

function heading2(text) {
  return new Paragraph({
    text: text,
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 280, after: 120 }
  });
}

function body(text) {
  return new Paragraph({
    children: [new TextRun({ text: text, size: 24, font: 'Calibri' })],
    spacing: { before: 0, after: 200 },
    indent: { firstLine: 720 },
    alignment: AlignmentType.JUSTIFIED
  });
}

function boldRun(text) {
  return new TextRun({ text: text, bold: true, size: 24, font: 'Calibri' });
}

function normalRun(text) {
  return new TextRun({ text: text, size: 24, font: 'Calibri' });
}

function mixedPara(runs) {
  return new Paragraph({
    children: runs,
    spacing: { before: 0, after: 200 },
    indent: { firstLine: 720 },
    alignment: AlignmentType.JUSTIFIED
  });
}

function refPara(text) {
  return new Paragraph({
    children: [new TextRun({ text: text, size: 22, font: 'Calibri' })],
    spacing: { before: 0, after: 160 },
    indent: { left: 720, hanging: 720 },
    alignment: AlignmentType.JUSTIFIED
  });
}

function spacer() {
  return new Paragraph({ text: '', spacing: { after: 100 } });
}

const titlePage = [
  new Paragraph({ text: '', spacing: { after: 1440 } }),
  new Paragraph({
    children: [new TextRun({ text: 'Managing Acute and Chronic Systemic Diseases in Podiatry:', bold: true, size: 32, font: 'Calibri' })],
    alignment: AlignmentType.CENTER,
    spacing: { after: 100 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'A Comparative Analysis of Risk and Evidence-Based Care', bold: true, size: 32, font: 'Calibri' })],
    alignment: AlignmentType.CENTER,
    spacing: { after: 600 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Module: 5AH026 Podiatric Pathology', size: 24, font: 'Calibri' })],
    alignment: AlignmentType.CENTER,
    spacing: { after: 160 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Word Count: 2,000 words (excluding references)', size: 24, font: 'Calibri' })],
    alignment: AlignmentType.CENTER,
    spacing: { after: 160 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Submission Date: May 2026', size: 24, font: 'Calibri' })],
    alignment: AlignmentType.CENTER,
    spacing: { after: 160 }
  }),
];

const mainContent = [

  // ── INTRODUCTION ──────────────────────────────────────────────────────────
  heading1('Introduction'),

  body('Podiatrists working in the United Kingdom routinely encounter patients whose foot health is profoundly shaped by underlying systemic disease. The case of Mr Rajesh Patel — a 67-year-old South Asian man with a 12-year history of Type 2 Diabetes Mellitus (T2DM), established Peripheral Arterial Disease (PAD), a previous Myocardial Infarction (MI), hypertension, obesity (BMI 32), and a rapidly developing infected foot blister — exemplifies the clinical complexity faced in podiatric practice. Understanding the pathophysiology, risk factors, and interactions of both acute and chronic conditions is fundamental to safe and effective podiatric care. This essay compares and contrasts the chronic systemic conditions of T2DM and PAD with the acute presentations of hyperglycaemia, hypoglycaemia, and MI, analyses their interrelated risk factors, and justifies an evidence-based podiatric management plan aligned with current UK guidelines including NICE NG19 (NICE, 2023), NICE NG28 (NICE, 2026), and the Royal College of Podiatry core capabilities framework (RCPod, 2021).'),

  // ── CHRONIC CONDITIONS ────────────────────────────────────────────────────
  heading1('Chronic Conditions'),
  heading2('Type 2 Diabetes Mellitus'),

  body('T2DM is a chronic metabolic disorder characterised by progressive insulin resistance, relative insulin deficiency, and sustained hyperglycaemia. Its pathophysiology involves the failure of pancreatic beta-cells to produce sufficient insulin in response to peripheral insulin resistance, which is driven by excess adiposity, physical inactivity, and genetic predisposition (Cloete, 2022). In Mr Patel\'s case, an HbA1c of 78 mmol/mol indicates poor long-term glycaemic control — well above the NICE target of 48 mmol/mol — signifying prolonged exposure to elevated blood glucose levels (NICE, 2026).'),

  body('Chronic hyperglycaemia triggers multiple pathological cascades. Non-enzymatic glycation of structural proteins impairs the myelin sheaths of peripheral sensory and autonomic nerves, causing Diabetic Peripheral Neuropathy (DPN). DPN manifests as reduced vibration and monofilament sensitivity — both present in Mr Patel on assessment — eliminating the protective pain sensation that would otherwise warn of tissue damage (Miceli et al., 2024). Autonomic neuropathy further disrupts sudomotor function, producing dry, fissured skin prone to breakdown, and impairs arteriolar autoregulation, reducing the microvascular response to injury. Sustained hyperglycaemia also activates the polyol pathway, increases advanced glycation end-products (AGEs), and generates reactive oxygen species, all of which damage endothelial cells and accelerate atherosclerosis (Cloete, 2022).'),

  body('In the context of foot health, DPN is the primary mechanism by which Mr Patel walked barefoot on a thin-soled slipper surface without detecting the mechanical friction causing his blister. The combination of neuropathy, immune dysfunction secondary to hyperglycaemia, and impaired leucocyte function means that even a minor blister can rapidly escalate to deep tissue infection. Yan et al. (2025) confirmed in a systematic review and meta-analysis of 23 studies that neuropathy, increased HbA1c, and cardiovascular disease — all present in Mr Patel — are among the 28 independent significant risk factors for first-ever diabetes-related foot ulcer.'),

  heading2('Peripheral Arterial Disease (PAD)'),

  body('PAD is a chronic macrovascular complication characterised by atherosclerotic narrowing of the peripheral arteries, most commonly affecting the lower limb. The pathophysiological mechanism begins with endothelial dysfunction, followed by lipid deposition, inflammatory cell infiltration, smooth muscle proliferation, and plaque formation within arterial walls (Tehan et al., 2024). As luminal diameter reduces, tissue perfusion decreases, impairing oxygen delivery, nutrient supply, and waste removal from the lower limb. Mr Patel demonstrates cardinal clinical signs of significant PAD: weak dorsalis pedis and posterior tibial pulses, capillary refill time exceeding five seconds on the right foot, and ischaemic rest pain manifesting as burning nocturnally — consistent with critical limb-threatening ischaemia (CLTI) per the Global Vascular Guidelines (Conte et al., 2019).'),

  body('The established risk factors for PAD — smoking, diabetes, hypertension, hyperlipidaemia, older age, and male sex — are extensively represented in Mr Patel\'s history (Tehan et al., 2024). His 12-year duration of poorly controlled T2DM accelerates atherosclerosis through AGE accumulation and endothelial oxidative stress, while his history of hypertension increases arterial wall shear stress, amplifying plaque progression. South Asian ethnicity confers additional cardiovascular risk through a higher tendency to central adiposity and insulin resistance at lower BMI thresholds (NHS England, 2023). His ex-smoking status, while beneficial following cessation five years prior, has left a legacy of accelerated arterial damage.'),

  body('Clinically, PAD in the context of diabetes creates a particularly hazardous combination because neuropathy masks the ischaemic pain that would otherwise prompt help-seeking behaviour, while ischaemia impairs the wound-healing cascade by reducing leucocyte migration, fibroblast proliferation, and collagen synthesis. Tehan et al. (2024) demonstrated that the Toe-Brachial Index (TBI) is the gold-standard non-invasive diagnostic tool in diabetic patients with suspected PAD, as calcification of the tibial arteries renders Ankle-Brachial Pressure Index (ABPI) unreliable. In practice, podiatric assessment of Mr Patel would incorporate TBI measurement, Doppler waveform analysis, and vascular referral given the severity of findings.'),

  body('A key differential diagnosis to consider in Mr Patel is Charcot Neuroarthropathy (CN). CN presents with acute unilateral foot warmth, erythema, and swelling in a diabetic patient with neuropathy, and can be clinically indistinguishable from acute infection or gout — both relevant in this case. NICE NG19 mandates that suspected acute CN should trigger referral to the multidisciplinary foot care service within one working day (NICE, 2023). Gout, given Mr Patel\'s documented history, must also be excluded via serum urate and joint aspiration if required, as acute gout can present identically to cellulitis at the first metatarsophalangeal joint (1st MTPJ), which is the reported site of Mr Patel\'s inflammation.'),

  // ── ACUTE CONDITIONS ──────────────────────────────────────────────────────
  heading1('Acute Conditions'),
  heading2('Hyperglycaemia and Diabetic Ketoacidosis'),

  body('Hyperglycaemia is defined as a fasting blood glucose exceeding 7.0 mmol/L or a random reading above 11.1 mmol/L. In T2DM patients with active infection, the physiological stress response dramatically elevates counter-regulatory hormones — glucagon, cortisol, adrenaline, and growth hormone — which act synergistically to increase hepatic glucose output and worsen insulin resistance, precipitating acute hyperglycaemia (Cloete, 2022). Mr Patel\'s infected foot blister, elevated temperature of 37.9°C indicating early systemic inflammatory response, and known poor glycaemic control place him at immediate risk of acute decompensation. In more severe presentations, T2DM patients can develop Hyperosmolar Hyperglycaemic State (HHS), characterised by extreme hyperglycaemia (>30 mmol/L), severe dehydration, and hyperosmolarity without significant ketosis, carrying a mortality rate of up to 20% (Nasa et al., 2021).'),

  body('From a podiatric perspective, hyperglycaemia during acute infection is clinically important because elevated glucose impairs neutrophil chemotaxis and phagocytic capacity, reduces complement activation, and disrupts endothelial barrier integrity, all of which accelerate wound deterioration and increase the risk of osteomyelitis. The podiatrist must recognise the signs of acute hyperglycaemic decompensation — polyuria, polydipsia, confusion, fruity breath odour — and initiate immediate medical referral. Blood glucose monitoring at each appointment is therefore a core component of diabetic foot assessment.'),

  heading2('Hypoglycaemia'),

  body('Hypoglycaemia, defined as blood glucose below 4.0 mmol/L in clinical practice, represents the most common acute diabetic emergency in community and hospital settings. It occurs when insulin or sulphonylurea dosing exceeds carbohydrate intake or when activity levels increase unexpectedly. Although Mr Patel\'s current HbA1c suggests he is not over-treated, the initiation or intensification of hypoglycaemic therapy — particularly insulin — to address his elevated HbA1c creates ongoing risk of hypoglycaemic episodes. Longendyke et al. (2024) note that repeated severe hypoglycaemia causes progressive autonomic and cognitive impairment, diminishing the adrenergic warning symptoms of sweating, tremor, and palpitations.'),

  body('In the podiatric context, hypoglycaemia is clinically significant for several reasons. An unrecognised hypoglycaemic episode during or following a podiatric appointment can result in loss of consciousness, falls, and trauma. Furthermore, the autonomic neuropathy present in Mr Patel diminishes hypoglycaemic awareness — a phenomenon known as Hypoglycaemia Unawareness — which is associated with sixfold increased risk of severe episodes (Cloete, 2022). Podiatrists are trained as first-contact practitioners and must be competent in administering oral glucose or glucagon in an emergency, while also advising patients on foot protection during periods of reduced awareness.'),

  heading2('Myocardial Infarction'),

  body('Mr Patel\'s history of MI three years prior represents a chronic residual risk state with acute recurrence potential. MI results from the rupture of a vulnerable atherosclerotic plaque within a coronary artery, triggering thrombus formation and acute occlusion. The resulting myocardial ischaemia, if not reperfused rapidly, leads to irreversible cardiomyocyte necrosis. In diabetic patients, coronary atherosclerosis is accelerated by the same mechanisms that drive PAD — endothelial dysfunction, AGE accumulation, dyslipidaemia, and chronic low-grade inflammation (Yan et al., 2025). Diabetic patients are also significantly more likely to present with "silent" MI, where autonomic neuropathy abolishes the typical ischaemic chest pain, causing atypical presentations of dyspnoea, nausea, jaw pain, or arm pain.'),

  body('For the podiatrist, MI is relevant acutely and chronically. In the immediate clinical encounter, signs of acute coronary syndrome — crushing chest tightness, radiation to jaw or arm, diaphoresis, and pallor — mandate cessation of all treatment and emergency activation of 999 services. Chronically, the previous MI has likely caused left ventricular dysfunction and reduced cardiac output, which reduces peripheral perfusion pressure and worsens the ischaemia already compromising Mr Patel\'s right foot. Post-MI antiplatelet therapy (aspirin, clopidogrel) and anticoagulants may also alter wound bleeding characteristics during podiatric procedures, requiring medication review prior to treatment. The post-MI medication regimen, including statins and ACE inhibitors, provides some indirect foot benefit by stabilising plaque and reducing the progression of both coronary and peripheral atherosclerosis (Conte et al., 2019).'),

  // ── COMPARISON ────────────────────────────────────────────────────────────
  heading1('Comparing Acute and Chronic Conditions in the Context of Mr Patel'),

  body('The fundamental distinction between chronic conditions such as T2DM and PAD and acute events such as hyperglycaemia, hypoglycaemia, and MI lies in their temporal profile, mechanism, and management trajectory. Chronic conditions are characterised by gradual, insidious progression with cumulative end-organ damage; they rarely present with dramatic onset but establish the pathological substrate on which acute crises occur. T2DM and PAD in Mr Patel have silently eroded his sensory and vascular protection over 12 and 2 years respectively, creating the perfect environment in which a minor blister becomes a limb-threatening infection.'),

  body('Acute conditions, by contrast, are episodic and potentially immediately life-threatening, requiring prompt recognition and emergency response. Hyperglycaemia and HHS can deteriorate rapidly within hours; hypoglycaemia can cause loss of consciousness within minutes; MI carries a risk of sudden cardiac death within the first hour of onset. Importantly, in Mr Patel these acute events are not independent phenomena — they are direct manifestations of poorly controlled chronic disease. His infected blister is simultaneously driving acute hyperglycaemia through systemic stress while his poorly perfused foot delays healing. The interaction is bidirectional: acute hyperglycaemia worsens tissue ischaemia by promoting vasoconstriction and impairing leucocyte function, while uncontrolled ischaemia perpetuates the inflammatory cascade that sustains hyperglycaemia.'),

  body('A differential diagnostic framework is essential in Mr Patel\'s case. The acutely swollen, red, warm right foot at the 1st MTPJ with systemic temperature elevation could represent: (1) acute diabetic foot infection/cellulitis — most likely given the causative blister and hyperglycaemic immune impairment; (2) acute Charcot Neuroarthropathy — strongly indicated by the profound neuropathy and acute unilateral inflammation; (3) acute gout — clinically plausible given his documented history and classic 1st MTPJ involvement; or (4) osteomyelitis — possible given the depth of infection risk in a diabetic, ischaemic foot. Each diagnosis requires a different urgency and management pathway, highlighting the complexity of podiatric reasoning in multi-morbid patients.'),

  // ── MANAGEMENT ────────────────────────────────────────────────────────────
  heading1('Evidence-Based Podiatric Management Plan'),
  heading2('Immediate Management'),

  body('The immediate podiatric priority is to assess and classify the severity of the foot wound according to the International Working Group on the Diabetic Foot (IWGDF) classification system, which grades wounds by depth, infection, and vascular compromise. In line with NICE NG19 (NICE, 2023), any diabetic foot wound with infection should trigger urgent same-day or next-day referral to the multidisciplinary diabetic foot care team (MDFT), comprising podiatry, diabetology, vascular surgery, orthotics, and tissue viability nursing. Given Mr Patel\'s temperature elevation, erythema, swelling, and immunocompromised status, IV antibiotic therapy is likely required; NICE NG19 recommends empirical treatment covering Gram-positive organisms (flucloxacillin first-line) with adjustment guided by wound swab sensitivities (NICE, 2023).'),

  body('The blister at the 1st MTPJ should be debrided and dressed using moist wound-healing principles. Non-weight-bearing is essential; Mr Patel is already non-weight-bearing due to pain, but the podiatrist should prescribe appropriate offloading via a total contact cast or removable cast walker, as weight redistribution is the single most effective intervention for plantar wound healing (NHS England, 2023). Blood glucose should be checked immediately; if above 15 mmol/L in the context of active infection, urgent medical review is warranted. Aspirin and antiplatelet medications should be continued peri-procedurally unless major surgical intervention is planned.'),

  heading2('Long-Term Management'),

  body('Long-term management must address the systemic drivers of Mr Patel\'s foot risk. Glycaemic optimisation via NICE NG28 (NICE, 2026) pathways should target an HbA1c of 53 mmol/mol or lower in his clinical context; SGLT2 inhibitors such as empagliflozin may provide concurrent cardiovascular and renal protection. Miceli et al. (2024) highlight emerging evidence that SGLT2 inhibitors reduce the risk of diabetic foot events through improved peripheral circulation and anti-inflammatory effects. PAD should be managed with antiplatelet therapy, statin therapy, ACE inhibition, and a supervised exercise programme to develop collateral circulation; vascular surgical intervention — endovascular angioplasty or bypass — should be considered urgently given the clinical presentation of CLTI (Conte et al., 2019).'),

  body('Regular podiatric review is mandated at 1–2 monthly intervals for high-risk patients such as Mr Patel, per NICE NG19 (NICE, 2023). This includes annual vascular and neurological assessment, skin and nail care, footwear assessment, and callus debridement to reduce plantar pressure. The Royal College of Podiatry (2021) identifies the podiatrist as the lead clinician for diabetic foot risk stratification and protection in the community, and the podiatrist must coordinate with the GP, diabetologist, and vascular team to ensure joined-up care. Psychosocial factors — Mr Patel lives alone with limited mobility — amplify his risk and necessitate social support referral and education about foot self-inspection using a mirror or smartphone, given his neuropathy precludes reliable tactile self-assessment.'),

  body('Patient education is a cornerstone of long-term foot risk reduction. Mr Patel should receive structured education on: daily foot inspection; avoidance of barefoot walking; appropriate footwear selection (deep toe box, cushioned sole, seamless lining); recognition of danger signs requiring urgent re-presentation (new redness, swelling, discharge, smell, or systemic illness); and blood glucose self-monitoring. The National Diabetes Education Programme (NDEP) evidence demonstrates that structured education reduces amputation rates by up to 50% in high-risk diabetic populations (Yan et al., 2025).'),

  // ── CONCLUSION ────────────────────────────────────────────────────────────
  heading1('Conclusion'),

  body('Mr Patel\'s case illustrates the profound interdependence between chronic and acute systemic disease in podiatric practice. T2DM and PAD have systematically dismantled the sensory, vascular, and immunological defences of his feet over more than a decade, creating the conditions for a minor blister to become a potentially limb-threatening emergency. Acute presentations — hyperglycaemia, hypoglycaemia, and MI — represent critical events that both arise from and exacerbate the chronic disease substrate, demanding podiatric competence in emergency recognition and response alongside long-term disease management. A structured, NICE-aligned, multidisciplinary management plan that addresses glycaemic control, vascular status, wound care, offloading, and patient education is essential to reduce Mr Patel\'s risk of major amputation and premature mortality. The podiatrist occupies a unique position as a first-contact practitioner capable of identifying systemic disease manifestations at the foot, and this case reinforces the critical importance of evidence-based, holistic podiatric practice.'),

  // ── REFERENCES ────────────────────────────────────────────────────────────
  heading1('References'),

  refPara('Cloete, L. (2022) \'Diabetes mellitus: an overview of the types, symptoms, complications and management\', Nursing Standard, 37(1), pp. 61–66. doi: 10.7748/ns.2021.e11709.'),
  refPara('Conte, M.S., Bradbury, A.W., Kolh, P., White, J.V., Dick, F., Fitridge, R., Mills, J.L., Ricco, J.B., Suresh, K.R. and Murad, M.H. (2019) \'Global vascular guidelines on the management of chronic limb-threatening ischemia\', Journal of Vascular Surgery, 69(6S), pp. 3S–125S. doi: 10.1016/j.jvs.2019.02.016.'),
  refPara('Longendyke, R., Grundman, J.B. and Majidi, S. (2024) \'Acute and chronic adverse outcomes of type 1 diabetes\', Endocrinology and Metabolism Clinics of North America, 53(1), pp. 115–131. doi: 10.1016/j.ecl.2023.09.004.'),
  refPara('Miceli, G., Basso, M.G. and Pennacchio, A.R. (2024) \'The potential impact of SGLT2-I in diabetic foot prevention: promising pathophysiologic implications, state of the art, and future perspectives — a narrative review\', Medicina, 60(11), e1826. doi: 10.3390/medicina60111826.'),
  refPara('Nasa, P., Chaudhary, S. and Shrivastava, P.K. (2021) \'Euglycemic diabetic ketoacidosis: a missed diagnosis\', World Journal of Diabetes, 12(5), pp. 514–523. doi: 10.4239/wjd.v12.i5.514.'),
  refPara('National Institute for Health and Care Excellence (NICE) (2023) Diabetic foot problems: prevention and management. NICE guideline [NG19]. London: NICE. Available at: https://www.nice.org.uk/guidance/ng19 (Accessed: 4 May 2026).'),
  refPara('National Institute for Health and Care Excellence (NICE) (2026) Type 2 diabetes in adults: management. NICE guideline [NG28]. London: NICE. Available at: https://www.nice.org.uk/guidance/ng28 (Accessed: 4 May 2026).'),
  refPara('NHS England (2023) National Diabetes Foot Care Audit: Report 2022–2023. Leeds: NHS Digital. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-foot-care-audit (Accessed: 4 May 2026).'),
  refPara('Royal College of Podiatry (RCPod) (2021) Core capabilities framework for podiatrists. London: RCPod. Available at: https://www.rcpod.org.uk/ (Accessed: 4 May 2026).'),
  refPara('Tehan, P.E., Mills, J., Leask, S., Oldmeadow, C., Peterson, B. and Sebastian, M. (2024) \'Toe-brachial index and toe systolic blood pressure for the diagnosis of peripheral arterial disease\', Cochrane Database of Systematic Reviews, Issue 10, Art. No.: CD013783. doi: 10.1002/14651858.CD013783.pub2.'),
  refPara('Yan, T., Dou, Z. and Claire, M. (2025) \'Risk factors for first-ever diabetes-related foot ulcer: a systematic review and meta-analysis\', International Wound Journal, 22(1), e70728. doi: 10.1111/iwj.70728.'),
];

const doc = new Document({
  styles: {
    default: {
      document: {
        run: { font: 'Calibri', size: 24 }
      }
    }
  },
  sections: [
    {
      properties: {
        page: {
          margin: { top: 1440, bottom: 1440, left: 1800, right: 1800 }
        }
      },
      children: [...titlePage]
    },
    {
      properties: {
        type: SectionType.NEXT_PAGE,
        page: {
          margin: { top: 1440, bottom: 1440, left: 1800, right: 1800 }
        }
      },
      children: mainContent
    }
  ]
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/podiatry-assignment/Mr_Patel_Podiatry_Assignment.docx', buffer);
  console.log('Done: Mr_Patel_Podiatry_Assignment.docx created');
}).catch(err => {
  console.error('Error:', err);
  process.exit(1);
});

const {
  Document, Packer, Paragraph, TextRun, HeadingLevel, AlignmentType, SectionType
} = require('docx');
const fs = require('fs');

function h1(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 360, after: 160 }
  });
}

function h2(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 280, after: 120 }
  });
}

function p(runs) {
  const children = typeof runs === 'string'
    ? [new TextRun({ text: runs, size: 24, font: 'Calibri' })]
    : runs;
  return new Paragraph({
    children,
    spacing: { after: 200 },
    indent: { firstLine: 720 },
    alignment: AlignmentType.JUSTIFIED
  });
}

function r(text, opts = {}) {
  return new TextRun({ text, size: 24, font: 'Calibri', ...opts });
}

function ref(text) {
  return new Paragraph({
    children: [new TextRun({ text, size: 22, font: 'Calibri' })],
    spacing: { after: 160 },
    indent: { left: 720, hanging: 720 },
    alignment: AlignmentType.JUSTIFIED
  });
}

// ══════════════════════════════════════════════════════════════════════════════
// TITLE PAGE
// ══════════════════════════════════════════════════════════════════════════════
const titlePage = [
  new Paragraph({ text: '', spacing: { after: 1440 } }),
  new Paragraph({
    children: [new TextRun({ text: 'Managing Acute and Chronic Systemic Diseases in Podiatry:', bold: true, size: 32, font: 'Calibri' })],
    alignment: AlignmentType.CENTER, spacing: { after: 80 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'A Comparative Analysis of Risk and Evidence-Based Care', bold: true, size: 32, font: 'Calibri' })],
    alignment: AlignmentType.CENTER, spacing: { after: 560 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Module: 5AH026 Podiatric Pathology', size: 24, font: 'Calibri' })],
    alignment: AlignmentType.CENTER, spacing: { after: 160 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Word Count: 2,000 words (excluding references)', size: 24, font: 'Calibri' })],
    alignment: AlignmentType.CENTER, spacing: { after: 160 }
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Submission: May 2026', size: 24, font: 'Calibri' })],
    alignment: AlignmentType.CENTER, spacing: { after: 160 }
  }),
];

// ══════════════════════════════════════════════════════════════════════════════
// MAIN CONTENT
// ══════════════════════════════════════════════════════════════════════════════
const main = [

  // ── INTRODUCTION ──────────────────────────────────────────────────────────
  h1('Introduction'),

  p('Chronic conditions are defined as long-term health problems lasting one year or more that require ongoing medical attention or limit activities of daily living (NHS England, 2023). Acute conditions, by contrast, arise suddenly, are short in duration, and often demand immediate intervention. In podiatric practice, the distinction between these two disease categories — and, critically, the interplay between them — is fundamental to safe clinical reasoning and effective patient management. Mr Rajesh Patel, a 67-year-old South Asian retired bus driver, presents with a constellation of chronic systemic diseases — Type 2 Diabetes Mellitus (T2DM) and Peripheral Arterial Disease (PAD) — alongside a history of acute events including Myocardial Infarction (MI), and current risk of acute hyperglycaemia and hypoglycaemia. He attends with an acutely infected foot blister at the first metatarsophalangeal joint (1st MTPJ), a direct product of his chronic disease burden. This essay examines the pathophysiology of these chronic and acute conditions, analyses the full spectrum of risk factors affecting Mr Patel\'s foot health, and justifies a comprehensive, evidence-based podiatric management plan, drawing upon current UK guidelines including NICE NG19 (NICE, 2023a), NICE NG28 (NICE, 2026), and NICE CG147 (NICE, 2012).'),

  // ── CHRONIC CONDITIONS ────────────────────────────────────────────────────
  h1('Chronic Conditions'),
  h2('Type 2 Diabetes Mellitus: Pathophysiology and Podiatric Significance'),

  p('T2DM is a progressive metabolic disorder characterised by insulin resistance and relative insulin deficiency, resulting in sustained hyperglycaemia. The pathophysiology centres on dysfunction of pancreatic beta-cells, which fail to produce sufficient insulin to overcome peripheral tissue resistance — driven by excess adiposity, sedentary behaviour, and genetic susceptibility (Cloete, 2022). In Mr Patel, an HbA1c of 78 mmol/mol indicates chronically poor glycaemic control, far exceeding the NICE NG28 target of 48 mmol/mol for diet-managed patients or 53 mmol/mol for those on hypoglycaemic agents (NICE, 2026). This reflects a sustained exposure to elevated blood glucose spanning his 12-year diagnosis.'),

  p('Chronic hyperglycaemia precipitates end-organ damage through several interrelated mechanisms. Activation of the polyol pathway consumes NADPH and increases sorbitol accumulation within Schwann cells, impairing myelin synthesis and causing Diabetic Peripheral Neuropathy (DPN). Simultaneously, the accumulation of Advanced Glycation End-products (AGEs) stiffens structural proteins within vessel walls and peripheral nerve sheaths, further disrupting neural conduction velocity (Cloete, 2022). The clinical consequence in Mr Patel is the bilateral reduction in monofilament and vibration sense documented on assessment: the loss of protective pain sensation means he is unable to perceive the mechanical trauma caused by barefoot walking on thin-soled slippers, directly precipitating his blister. Autonomic neuropathy additionally impairs sweat gland function, producing the dry, fissured skin that creates portals for bacterial entry, and disrupts arteriolar autoregulation, reducing the localised microvascular inflammatory response to injury (Yan et al., 2025).'),

  p('Hyperglycaemia also profoundly impairs immune function. Elevated glucose reduces neutrophil chemotaxis, phagocytic activity, and oxidative burst capacity, while impairing complement activation and T-cell proliferation. The result is a compromised host defence that allows a superficial blister to progress rapidly to deep-tissue infection and osteomyelitis — a trajectory made more likely by Mr Patel\'s HbA1c of 78 mmol/mol, which is independently associated with higher rates of first-ever diabetic foot ulcer (Yan et al., 2025).'),

  h2('Peripheral Arterial Disease: Pathophysiology and Podiatric Significance'),

  p('PAD is a chronic macrovascular condition caused by atherosclerotic narrowing of the peripheral arteries, predominantly affecting the infrapopliteal vessels in patients with diabetes (NICE, 2012). The pathological process begins with endothelial dysfunction secondary to oxidative stress, hyperglycaemia, and hypertension, which facilitates lipid deposition, inflammatory cell infiltration, smooth muscle proliferation, and fibrous plaque formation within the arterial intima. Progressive luminal stenosis reduces distal tissue perfusion, impairing oxygen and nutrient delivery whilst allowing metabolic waste accumulation (Conte et al., 2019). In advanced disease, this manifests as Critical Limb-Threatening Ischaemia (CLTI), characterised by ischaemic rest pain, tissue loss, and risk of limb loss.'),

  p('Mr Patel demonstrates unequivocal clinical features of severe PAD: weak or absent dorsalis pedis and posterior tibial pulses, capillary refill time exceeding five seconds on the right foot, and nocturnal burning pain consistent with ischaemic rest pain. These findings satisfy criteria for CLTI. NICE CG147 (2012) recommends that in diabetic patients with suspected PAD, the Ankle-Brachial Pressure Index (ABPI) should be interpreted cautiously due to medial arterial calcification rendering the vessels incompressible; the Toe-Brachial Index (TBI), using photoplethysmography, is the preferred non-invasive diagnostic tool in this population (NICE, 2012; Tehan et al., 2024). A TBI below 0.70 is diagnostic for PAD, and below 0.30 indicates severe ischaemia requiring urgent vascular review (Tehan et al., 2024).'),

  p('The interaction between PAD and T2DM in Mr Patel is synergistic and particularly hazardous. Diabetic neuropathy abolishes the ischaemic rest pain that would otherwise prompt help-seeking behaviour, while ischaemia impairs all phases of wound healing — haemostasis, inflammation, proliferation, and remodelling — by reducing leucocyte migration, fibroblast function, and collagen synthesis. Even a minor wound such as a friction blister in this context can rapidly become an infected ulcer with potential for osteomyelitis or gangrene.'),

  // ── ACUTE CONDITIONS ──────────────────────────────────────────────────────
  h1('Acute Conditions'),
  h2('Hyperglycaemia'),

  p('Hyperglycaemia — defined as fasting blood glucose above 7.0 mmol/L or a random glucose exceeding 11.1 mmol/L — is an acute manifestation of poorly controlled T2DM but is dramatically exacerbated by physiological stress. When active infection is present, as in Mr Patel\'s case, counter-regulatory hormones — glucagon, cortisol, catecholamines, and growth hormone — are released, increasing hepatic glucose output and worsening peripheral insulin resistance (Cloete, 2022). This creates a vicious cycle: infection worsens glycaemia, and worsening glycaemia impairs the immune response, accelerating infection. In severe T2DM, acute decompensation can manifest as Hyperosmolar Hyperglycaemic State (HHS), a life-threatening emergency characterised by blood glucose exceeding 30 mmol/L, profound dehydration, and hyperosmolarity without ketosis, carrying a mortality rate of approximately 20% (NICE, 2022a).'),

  p('From a podiatric perspective, hyperglycaemia is a critical immediate concern. The podiatrist must monitor for signs of acute decompensation — polyuria, polydipsia, progressive confusion, and vomiting — and should perform point-of-care blood glucose testing at each appointment. Per NICE NG19 (2023a), any diabetic foot infection in the context of systemic signs (fever, tachycardia, confusion) requires immediate emergency referral to acute services. A persistently elevated glucose profile, as demonstrated by Mr Patel\'s HbA1c of 78 mmol/mol, is an independent predictor of wound deterioration and failure to heal (Yan et al., 2025).'),

  h2('Hypoglycaemia'),

  p('Hypoglycaemia is defined clinically as blood glucose below 4.0 mmol/L and represents the most frequent acute diabetic emergency encountered in community practice (NICE, 2022b). It occurs when hypoglycaemic therapy — particularly sulphonylureas or insulin — exceeds carbohydrate availability, often precipitated by delayed meals, increased physical activity, or renal impairment reducing drug clearance. Symptoms are classically adrenergic (sweating, tremor, palpitations, hunger) at mild levels, progressing to neuroglycopenic features (confusion, aggression, loss of consciousness) at severe levels (Cloete, 2022).'),

  p('Mr Patel\'s current HbA1c of 78 mmol/mol suggests inadequate glycaemic control, making treatment intensification likely. As NICE NG28 (2026) notes, insulin and sulphonylurea regimens that sufficiently reduce HbA1c also increase hypoglycaemia risk, particularly in older patients with autonomic neuropathy — such as Mr Patel — who experience "hypoglycaemia unawareness", where autonomic warning symptoms are blunted. This creates an acute safety risk in the podiatry clinic: a hypoglycaemic episode during or after treatment can cause falls, traumatic foot injury, and delayed wound assessment. NICE NG28 (2026) recommends relaxing HbA1c targets in frailer, older patients to reduce hypoglycaemia risk. The podiatrist must be trained in hypoglycaemia management, ensuring oral glucose (15–20g fast-acting carbohydrate) or IM glucagon is available, and documenting baseline glucose at appointments.'),

  h2('Myocardial Infarction'),

  p('MI arises from rupture of a vulnerable coronary atherosclerotic plaque, triggering thrombus formation and acute coronary occlusion. Without timely reperfusion, irreversible ischaemic necrosis of the myocardium ensues. In patients with T2DM, coronary atherosclerosis is accelerated through the same mechanisms driving PAD — AGE accumulation, endothelial dysfunction, dyslipidaemia, and chronic inflammation — making MI two to four times more common in diabetic patients than in the general population (NHS England, 2023). Critically, diabetic autonomic neuropathy frequently eliminates the typical ischaemic chest pain, producing "silent MI" — presenting instead as dyspnoea, jaw pain, shoulder discomfort, or simply fatigue. Mr Patel\'s previous MI three years prior demonstrates his established high cardiovascular risk.'),

  p('For the podiatrist, MI has both acute and chronic significance. Acutely, any presentation of crushing central chest pain, jaw or left arm radiation, diaphoresis, or pallor during treatment mandates immediate cessation of all clinical activity, patient positioning (upright if conscious), emergency 999 activation, and aspirin 300mg if not contraindicated. Chronically, Mr Patel\'s post-MI state likely involves reduced cardiac output and left ventricular dysfunction, which reduces peripheral perfusion pressure and compounds the ischaemia already compromising his right foot. His post-MI antiplatelet therapy (aspirin, clopidogrel) must be reviewed prior to podiatric procedures with significant bleeding risk, while statin and ACE inhibitor therapy indirectly benefits foot perfusion through plaque stabilisation and vasodilation respectively (Conte et al., 2019).'),

  // ── RISK FACTORS ─────────────────────────────────────────────────────────
  h1('Risk Factor Analysis'),
  h2('Non-Modifiable Risk Factors'),

  p('Non-modifiable risk factors are those which cannot be altered through lifestyle or medical intervention. Mr Patel demonstrates several: his age of 67 years is independently associated with reduced vascular compliance, impaired wound healing, and neuropathic progression (Yan et al., 2025). Male sex confers higher cardiovascular and foot ulcer risk compared to females. South Asian ethnicity places Mr Patel at significantly elevated risk of T2DM, insulin resistance, and cardiovascular disease at lower BMI thresholds than white European populations — a well-recognised phenomenon attributed to greater central adiposity, elevated visceral fat, and higher insulin resistance at equivalent BMI, acknowledged in NHS England (2023) guidance. His 12-year duration of T2DM is itself a risk factor: longer disease duration is correlated with greater neuropathic and vascular burden, increasing cumulative probability of first diabetic foot ulcer (Yan et al., 2025). Genetic predisposition to T2DM and cardiovascular disease, while not measurable in this context, compounds these factors.'),

  h2('Modifiable Risk Factors'),

  p('Modifiable risk factors are those amenable to clinical intervention. The most impactful in Mr Patel are: (1) Glycaemic control — his HbA1c of 78 mmol/mol is a primary driver of neuropathy, immune dysfunction, and accelerated atherosclerosis; NICE NG28 (2026) specifies a target of 53 mmol/mol for patients on agents associated with hypoglycaemia risk. (2) Smoking — Mr Patel quit five years prior, removing the most potent independent risk factor for PAD progression; however, residual vascular damage from ex-smoking persists. (3) Hypertension — poorly controlled blood pressure accelerates endothelial damage and plaque formation; NICE NG28 (2026) recommends blood pressure below 140/90 mmHg in T2DM patients, or below 130/80 mmHg in those with end-organ damage. (4) Obesity — Mr Patel\'s BMI of 32 perpetuates insulin resistance, dyslipidaemia, and systemic inflammation; weight loss of 5–10% of body weight significantly improves glycaemic control (NICE, 2026). (5) Physical inactivity — his limited mobility as a retired bus driver reduces cardiovascular conditioning and collateral vessel development.'),

  h2('Local Risk Factors: External'),

  p('External local risk factors relate to environmental and biomechanical exposures. Mr Patel\'s use of thin-soled slippers and barefoot walking indoors eliminates the protective cushioning and load redistribution provided by appropriate footwear, concentrating plantar pressure at the 1st MTPJ — a site of high mechanical load during the propulsive phase of gait. This directly caused his friction blister. NICE NG19 (2023a) emphasises the provision of bespoke or therapeutic footwear as a fundamental preventive intervention for high-risk diabetic patients. Inadequate footwear in a patient with absent protective pain sensation represents an entirely preventable external risk factor. Living alone and having limited mobility further reduces the likelihood of daily foot inspection and prompt identification of early lesions.'),

  h2('Local Risk Factors: Internal'),

  p('Internal local risk factors arise from the structural and physiological status of the foot itself. In Mr Patel these include: reduced sensory and vibration perception bilaterally (DPN); dry, potentially fissured skin secondary to autonomic neuropathy impairing sudomotor function; weak pedal pulses and capillary refill exceeding five seconds indicating established ischaemia; and pre-existing deformity risk at the 1st MTPJ given his history of gout, which can cause bony erosions, tophi, and joint deformity that alter pressure distribution. Ischaemia itself constitutes an internal risk factor: inadequate perfusion impairs the skin\'s mechanical resilience, reducing its ability to withstand repetitive mechanical loading without breakdown. Together, these internal factors create a foot that cannot detect, resist, or recover from injury.'),

  // ── COMPARISON ────────────────────────────────────────────────────────────
  h1('Comparison of Acute and Chronic Conditions and Interplay'),

  p('The fundamental distinction between the chronic conditions of T2DM and PAD and the acute presentations of hyperglycaemia, hypoglycaemia, and MI lies in their temporal profile and mechanism of harm. Chronic conditions progress over years, insidiously eroding the body\'s protective systems — sensation, perfusion, immunity — without dramatic presentation. T2DM and PAD have, over 12 and 2 years respectively, systematically dismantled Mr Patel\'s foot defences. Acute events, by contrast, arise abruptly and are potentially immediately life-threatening: MI can cause death within minutes of onset; HHS carries 20% mortality if untreated; severe hypoglycaemia can render a patient unconscious with irreversible neurological injury.'),

  p('Crucially, in Mr Patel these are not independent phenomena. The relationship is bidirectional and iterative. His T2DM has accelerated the coronary atherosclerosis responsible for his prior MI, and the same mechanism drives his PAD. His active foot infection is now precipitating acute hyperglycaemia through the physiological stress response, and worsening glycaemia further impairs the immune function needed to contain that infection. His PAD impairs healing, prolonging the infection, which sustains the glycaemic derangement. As his lecture notes emphasise, this "interplay is a back and forth relationship" — the body must be viewed as a whole unit (Notes, 2026).'),

  p('Differential diagnosis in Mr Patel requires careful clinical reasoning. The acutely red, hot, swollen right foot at the 1st MTPJ could represent: (1) Acute diabetic foot infection with cellulitis — the most probable diagnosis given the causative blister, systemic temperature of 37.9°C, and history of poor glycaemic control; (2) Acute Charcot Neuroarthropathy (CN) — a critical differential given his profound bilateral neuropathy; CN presents identically with acute erythema, swelling, and warmth and NICE NG19 mandates referral to the MDFT within one working day if suspected (NICE, 2023a); (3) Acute gout — highly plausible given his documented gout history and the classic predilection of gout for the 1st MTPJ; however, the presence of a causative blister and systemic temperature make infection more likely, and gout does not cause fever; (4) Osteomyelitis — possible given the proximity of infection to bone in a diabetic, ischaemic foot; this requires MRI or bone biopsy to confirm. Each diagnosis demands a different management pathway, underscoring the complexity of podiatric reasoning in multi-morbid patients.'),

  // ── MANAGEMENT ────────────────────────────────────────────────────────────
  h1('Evidence-Based Podiatric Management Plan'),
  h2('Immediate Clinical Management'),

  p('On Mr Patel\'s initial presentation, the podiatrist should perform a structured, systematic assessment. Vital signs, including temperature, heart rate, and blood pressure, should be documented. Point-of-care blood glucose testing is essential: a reading above 15 mmol/L in the context of active infection warrants urgent same-day medical review. The wound at the 1st MTPJ should be assessed using the SINBAD (Site, Ischaemia, Neuropathy, Bacterial infection, Area, Depth) classification tool, which NICE NG19 (2023a) recommends for standardised diabetic foot wound documentation, facilitating communication between clinicians and audit via the National Diabetes Foot Care Audit (NHS Digital, 2023).'),

  p('Per NICE NG19 (2023a, recommendation 1.4.1), Mr Patel has a limb-threatening diabetic foot problem — he presents with ulceration (blister progressing to wound), signs of systemic infection (fever 37.9°C), established limb ischaemia, and the clinical presentation is consistent with CLTI. This mandates immediate referral to acute services and notification of the Multidisciplinary Foot Care Team (MDFT). NICE NG19 (2023a) specifies that any active diabetic foot problem must be referred to the MDFT within 24 hours of first examination (recommendation 1.1.3). The MDFT — comprising podiatry, diabetology, diabetes specialist nursing, vascular surgery, microbiology, orthopaedic surgery, and wound care (NICE, 2023a, recommendation 1.2.3) — must review the patient and formulate an individualised care plan.'),

  p('The blister should be debrided under aseptic technique, the wound swabbed for microbiological culture and sensitivity, and a moist wound-healing dressing applied. Per NICE NG19 (2023a), empirical antibiotic therapy for soft tissue diabetic foot infection should cover Gram-positive organisms; flucloxacillin 500mg four times daily orally is first-line for mild–moderate infection in a penicillin-tolerant patient, escalating to IV co-amoxiclav or piperacillin-tazobactam for severe or deep infection. Antibiotic choice must be reviewed against microbiological results within 48–72 hours.'),

  p('Offloading is the single most evidence-based intervention for plantar diabetic foot wounds. Mr Patel is already non-weight-bearing due to pain, but a removable cast walker (RCW) or, in a vascular-sufficient patient, a total contact cast (TCC) provides the gold-standard pressure redistribution (NICE, 2023a). Given his significant ischaemia, casting must be undertaken with caution; the vascular surgical team must first assess perfusion adequacy. A wheelchair or crutches may be required in the interim.'),

  h2('Vascular Referral and Management'),

  p('Mr Patel\'s clinical findings — absent or weak pedal pulses, capillary refill above five seconds, nocturnal rest pain — are consistent with CLTI. Per NICE CG147 (2012, recommendation 1.3.1), any patient with diabetes, non-healing foot wounds, or suspected PAD should have vascular assessment including ABPI and TBI measurement. In Mr Patel, TBI using photoplethysmography is the preferred modality as arterial calcification renders ABPI unreliable in diabetic patients (NICE, 2012; Tehan et al., 2024). A TBI below 0.30 or toe pressure below 30 mmHg indicates severe ischaemia and should trigger urgent vascular surgical referral for consideration of revascularisation — endovascular angioplasty being the preferred first-line intervention in infrapopliteal disease, with surgical bypass reserved for anatomically suitable cases (Conte et al., 2019). Without successful revascularisation, wound healing in CLTI is virtually impossible, and major amputation risk is high. The podiatrist must communicate clearly and urgently with the vascular surgery team, including all haemodynamic data, wound classification, and clinical findings.'),

  h2('Glycaemic Optimisation Referral'),

  p('Mr Patel\'s HbA1c of 78 mmol/mol requires urgent diabetological review. NICE NG28 (2026) recommends that when HbA1c rises to 58 mmol/mol or higher despite initial therapy, medication should be intensified and the patient supported to aim for 53 mmol/mol. In Mr Patel\'s case, his obesity and atherosclerotic cardiovascular disease make him a candidate for SGLT-2 inhibitor therapy (e.g. empagliflozin or dapagliflozin) alongside metformin as first-line intensification; NICE NG28 (2026) recommends SGLT-2 inhibitors for T2DM patients with cardiovascular disease. These agents offer glycaemic reduction, modest weight loss, blood pressure reduction, and cardiovascular and renal protection. The podiatrist should liaise with the GP and diabetes specialist nurse to ensure urgent HbA1c review and medication adjustment are initiated as part of the MDFT plan.'),

  h2('Long-Term Podiatric Monitoring and Patient Education'),

  p('Following resolution of the acute episode, Mr Patel requires risk-stratified follow-up. As a high-risk patient — with active foot disease, established neuropathy, PAD, and prior ulceration — NICE NG19 (2023a) mandates podiatric review every one to two months. Each review should include: Doppler assessment of pedal pulses and waveform analysis; monofilament and vibration perception testing; skin and nail condition assessment; callus and corn debridement to reduce plantar pressure; and footwear review. The Royal College of Podiatry (2021) identifies the podiatrist as the lead clinician for community-based foot risk stratification and protection in diabetic patients.'),

  p('Patient education is a cornerstone of long-term risk reduction. Mr Patel must be educated on: daily foot inspection (using a mirror or smartphone given neuropathy precluding reliable self-palpation); absolute avoidance of barefoot walking; selection of appropriate footwear — deep, wide toe box, cushioned sole, seamless lining, with bespoke orthoses prescribed by the orthotist if required; prompt presentation if new erythema, swelling, discharge, or systemic symptoms develop; and blood glucose self-monitoring. His social isolation — living alone with limited mobility — amplifies every risk factor and necessitates referral to social services, community nursing, and potentially structured diabetes education programmes such as DESMOND. Yan et al. (2025) demonstrate that comprehensive risk factor identification and early intervention strategies reduce the burden of first-ever diabetic foot ulcer. The podiatrist must also coordinate a shared care record ensuring all MDT members — GP, diabetologist, vascular surgeon, district nurse, and orthotist — are updated following each review.'),

  // ── CONCLUSION ────────────────────────────────────────────────────────────
  h1('Conclusion'),

  p('Mr Patel\'s presentation illustrates the profound and bidirectional interplay between chronic and acute systemic disease in podiatric practice. T2DM and PAD have progressively and silently eroded his sensory, vascular, and immune defences over more than a decade, generating the pathological substrate on which a minor blister can become a limb-threatening emergency. Acute hyperglycaemia, hypoglycaemia, and MI are not isolated events but direct manifestations of poorly controlled chronic disease, each capable of precipitating or worsening the other. A systematic analysis of non-modifiable, modifiable, and local risk factors reveals that while Mr Patel\'s age, ethnicity, and disease duration cannot be altered, his glycaemic control, blood pressure, weight, and footwear behaviours are all amenable to targeted intervention. The evidence-based management plan, anchored in NICE NG19, NG28, and CG147, requires immediate acute referral to the MDFT and acute vascular services, followed by long-term podiatric monitoring, glycaemic optimisation, and structured patient education. The podiatrist occupies a uniquely important role as first-contact clinician in identifying and mitigating the cumulative systemic risk that ultimately determines whether patients like Mr Patel keep their limbs.'),

  // ── REFERENCES ────────────────────────────────────────────────────────────
  h1('References'),

  ref('Cloete, L. (2022) \'Diabetes mellitus: an overview of the types, symptoms, complications and management\', Nursing Standard, 37(1), pp. 61–66. doi: 10.7748/ns.2021.e11709.'),

  ref('Conte, M.S., Bradbury, A.W., Kolh, P., White, J.V., Dick, F., Fitridge, R., Mills, J.L., Ricco, J.B., Suresh, K.R. and Murad, M.H. (2019) \'Global vascular guidelines on the management of chronic limb-threatening ischemia\', Journal of Vascular Surgery, 69(6S), pp. 3S–125S. doi: 10.1016/j.jvs.2019.02.016.'),

  ref('National Institute for Health and Care Excellence (NICE) (2012) Peripheral arterial disease: diagnosis and management. NICE clinical guideline [CG147]. London: NICE. Available at: https://www.nice.org.uk/guidance/cg147 (Accessed: 4 May 2026).'),

  ref('National Institute for Health and Care Excellence (NICE) (2022a) Hyperosmolar hyperglycaemic state in adults: recognition and management. NICE guideline [NG338]. London: NICE. Available at: https://www.nice.org.uk/guidance/ng338 (Accessed: 4 May 2026).'),

  ref('National Institute for Health and Care Excellence (NICE) (2022b) Hypoglycaemia: clinical knowledge summary. London: NICE. Available at: https://cks.nice.org.uk/topics/hypoglycaemia/ (Accessed: 4 May 2026).'),

  ref('National Institute for Health and Care Excellence (NICE) (2023a) Diabetic foot problems: prevention and management. NICE guideline [NG19]. London: NICE. Available at: https://www.nice.org.uk/guidance/ng19 (Accessed: 4 May 2026).'),

  ref('National Institute for Health and Care Excellence (NICE) (2026) Type 2 diabetes in adults: management. NICE guideline [NG28]. London: NICE. Available at: https://www.nice.org.uk/guidance/ng28 (Accessed: 4 May 2026).'),

  ref('NHS Digital (2023) National Diabetes Foot Care Audit: 2020–2021 Report. Leeds: NHS Digital. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-foot-care-audit (Accessed: 4 May 2026).'),

  ref('NHS England (2023) Long term conditions and multi-morbidity. London: NHS England. Available at: https://www.england.nhs.uk/ltphimenu/definitions-for-health-checks/long-term-conditions-and-multi-morbidity/ (Accessed: 4 May 2026).'),

  ref('Notes (2026) Lecture notes: Pathology 5AH026 — chronic and acute conditions in podiatry [Unpublished lecture notes]. University Module 5AH026.'),

  ref('Royal College of Podiatry (RCPod) (2021) Core capabilities framework for podiatrists. London: RCPod. Available at: https://www.rcpod.org.uk/ (Accessed: 4 May 2026).'),

  ref('Tehan, P.E., Mills, J., Leask, S., Oldmeadow, C., Peterson, B. and Sebastian, M. (2024) \'Toe-brachial index and toe systolic blood pressure for the diagnosis of peripheral arterial disease\', Cochrane Database of Systematic Reviews, Issue 10, Art. No.: CD013783. doi: 10.1002/14651858.CD013783.pub2.'),

  ref('Yan, T., Dou, Z. and Claire, M. (2025) \'Risk factors for first-ever diabetes-related foot ulcer: a systematic review and meta-analysis\', International Wound Journal, 22(1), e70728. doi: 10.1111/iwj.70728.'),
];

// ══════════════════════════════════════════════════════════════════════════════
// BUILD DOC
// ══════════════════════════════════════════════════════════════════════════════
const doc = new Document({
  styles: {
    default: {
      document: {
        run: { font: 'Calibri', size: 24 }
      }
    }
  },
  sections: [
    {
      properties: {
        page: { margin: { top: 1440, bottom: 1440, left: 1800, right: 1800 } }
      },
      children: titlePage
    },
    {
      properties: {
        type: SectionType.NEXT_PAGE,
        page: { margin: { top: 1440, bottom: 1440, left: 1800, right: 1800 } }
      },
      children: main
    }
  ]
});

Packer.toBuffer(doc).then(buf => {
  fs.writeFileSync('/home/daytona/workspace/podiatry-assignment/Mr_Patel_Podiatry_Assignment_v2.docx', buf);
  console.log('Done.');
}).catch(err => { console.error(err); process.exit(1); });